Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5859058 | 0.99 | KDM4E (0.53) | KDM4EUSP2ALDH1A1AAK1NUDT1 | |
| SCHEMBL5857594 | 0.85 | KDM4E (0.60) | KDM4EUSP2ALDH1A1AAK1XDH | |
| Hydrochloric Acid SCHEMBL7855012 | 0.84 | KDM4E (0.58) | KDM4EUSP2ALDH1A1AAK1XDH | |
| SCHEMBL508229 | 0.79 | NUDT1 (0.47) | KDM4EUSP2ALDH1A1AAK1NUDT1 | |
| SCHEMBL6052133 | 0.79 | ALDH1A1 (0.56) | KDM4EUSP2ALDH1A1AAK1 | |
| SCHEMBL13723909 | 0.78 | GAA (0.57) | KDM4EUSP2ALDH1A1NUDT1 | |
| SCHEMBL17101854 | 0.77 | KDM4E (0.66) | KDM4EUSP2ALDH1A1XDH | |
| SCHEMBL14320713 | 0.77 | GAA (0.55) | KDM4EUSP2ALDH1A1NUDT1NPC1 | |
| SCHEMBL13665133 | 0.74 | ALDH1A1 (0.50) | KDM4EUSP2ALDH1A1AAK1NPC1 | |
| SCHEMBL6052309 | 0.73 | ALDH1A1 (0.63) | KDM4EUSP2ALDH1A1AAK1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112594-B2 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1310488-A1 | FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | BET1, NFATC1, ARG1 | KDM4E 474/4885USP2 4157/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.